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BACKGROUND: Patients and providers may be reluc-
tant to escalate to insulin therapy despite inadequate
glycemic control.
OBJECTIVES: To determine the proportion of patients
attaining and maintaining glycemic targets after initiat-
ing sulfonylurea and metformin oral combination ther-
apy (SU/MET); to assess insulin initiation among
patients failing SU/MET; and to estimate the glycemic
burden incurred, stratified by whether HbA1c goal was
attained and maintained.
DESIGN: Longitudinal observational cohort study.
SUBJECTS: Type 2 diabetes patients, 3,891, who newly
initiated SU/MET between 1 January 1996 and 31
December 2000.
MEASUREMENTS: Subjects were followed until insulin
was added, health plan disenrolment, or until 31
December 2005. We calculated the number of months
subjects continued SU/MET therapy alone, in total,
and during periods of inadequate glycemic control; the
A1C reached during those time periods; and total
glycemic burden, defined as the estimated cumulative
monthly difference between measured A1C and 8%.
RESULTS: Duringameanfollow-upof54.6±28.6months,
41.9% of the subjects added insulin, and 11.8% received
maximal doses of both oral agents. Over half of SU/MET
patients attained but failed to maintain A1C of 8%, yet
continued SU/MET therapy for an average of nearly
3 years, sustaining glycemic burden equivalent to nearly
32 months of A1C levels of 9%. Another 18% of patients
never attained the 8% goal with SU/MET, yet continued
that therapy for an average of 30 months, reaching mean
A1C levels of 10%.
CONCLUSIONS: Despite inadequate glycemic control, a
minority of patients added insulin or maximized oral
agent doses, thus, incurring substantial glycemic bur-
den on SU/MET. Additional studies are needed to
examine the benefits of rapid titration to maximum
doses and earlier initiation of insulin therapy.
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INTRODUCTION
Type 2 diabetes is a progressive disease that requires the ongoing
intensification of pharmacotherapy to achieve and maintain
glycemic control.
1 The micro- and probable macro-vascular
benefits of glycemic control are now well documented.
2–4 When
lifestyle modification alone can no longer maintain desired
glycemic targets and clinicians and patients decide to begin drug
therapy, sulfonylurea (SU) or metformin monotherapy are typi-
cally the first-line agents of choice.
5 These agents are frequently
used in combination after monotherapy fails, but the success of
SU/metformin combination therapy (SU/MET) is often short-
lived,
6withHbA1c(A1C)escalationresumingasearlyas6months
after SUs are added to metformin.
7
Because of progressive deficits in insulin secretion, patients
often need insulin supplementation to achieve good glycemic
control.
8 A recent consensus statement from the American
Diabetes Association (ADA) and the European Association for
the Study of Diabetes (EASD) recommended insulin as the
next therapy when combination metformin/sulfonylurea treat-
ment does not result in goal glycemia.
9 Prior studies have
consistently demonstrated that fewer than half of patients with
inadequate glycemic control intensify their antihyperglycemic
therapy, a concept known as “clinical inertia”.
10–12 This inertia
may be particularly problematic when insulin is the next
therapeutic option. Patients are often reluctant to initiate
insulin, perhaps because of an aversion to insulin injections,
a belief that they had failed proper diabetes self-management,
a concern that insulin would restrict their lives, or other
reasons.
13 Clinicians can also be reluctant to initiate insulin.
14
This patient and provider reluctance may lead to long periods
of unnecessarily high A1C, or “glycemic burden”. Brown et
al.
15 recently described glycemic burden among subjects
receiving SU/MET, but that study was limited to patients
whose therapy was escalated by adding insulin or another oral
agent. To our knowledge, no study to date has attempted to
quantify the glycemic burden of SU/MET among patients who
do and do not escalate pharmacotherapy. Our objectives were
to determine the proportion of patients attaining and main-
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453taining glycemic targets while receiving sulfonylurea and
metformin oral combination therapy (SU/MET), to assess
insulin initiation among patients failing SU/MET, and to
estimate the glycemic burden incurred, stratified by whether
HbA1c goal was attained and maintained.
RESEARCH DESIGN AND METHODS
The current study was conducted within Kaiser Permanente
Northwest (KPNW), a not-for-profit, group-model health main-
tenance organization (HMO) that provides comprehensive,
prepaid coverage to about 470,000 members. KPNW uses
electronic health care utilization data to track and facilitate
operations. An electronic medical record, in use since 1996,
allows the attending clinician to record as many as 20 ICD-9-
CM coded diagnoses at each ambulatory patient contact and up
to nine discharge diagnoses for inpatient hospital admissions.
An electronic problem list, also coded in ICD-9-CM, is available
to the clinician at each contact. A single regional laboratory
performs all KPNW laboratory tests, and the results are stored
inasearchable database. Apharmacy is locatedineachmedical
office, and most members have a pharmacy benefit, helping to
ensure complete capture of pharmaceutical dispenses. In the
current study, 96% of subjects had a pharmacy benefit.
KPNWemploys evidence-based guidelines to assist clinicians
intheirtreatmentdecisions. Duringthecourseofthisstudy, the
antihyperglycemic therapy guideline algorithm recommended
SU as the first-line agent, followed by addition of metformin,
when necessary, and then insulin therapy when A1C was
greater than 8%. From all KPNW members with type 2 diabetes
(multiple ICD-9-CM diagnoses of 250.xx), we selected all 5,300
who newly initiated SU/MET between 1 January 1996 and 31
December 2000 (by adding one agent to an ongoing regimen or
by simultaneously initiating both drugs) and who maintained
SU/MET for at least 6 months. We excluded 900 subjects who
did not have at least 6 months of health plan eligibility before
and after SU/MET initiation. To focus the study on the
recommended therapeutic progression from SU/MET to insu-
lin, we excluded 414 subjects who received a third oral agent
before insulin. We also excluded 95 subjects who did not have at
least one A1C measurement during both the 6-month period
before and the 6-month period after SU/MET initiation. Apply-
ing all of these criteria resulted in a final analysis sample of
3,891. Our primary end point was the addition of insulin to the
patient’s treatment regimen. We followed subjects until insulin
was added, health plan eligibility ended (because of disenrol-
ment or death), or until 31 December 2005.
We examined all A1C measurements (Diamat assay, Bio-
Rad, Hercules, CA) recorded in the KPNW regional laboratory
database during the observation period (which corresponded
to use of SU/MET alone). During the observation period, the
recommended A1C level for therapeutic action was 8%. Using
this level as the A1C goal, we calculated three measures of the
degree to which patients failed to meet the goal. First, we
calculated the number of months subjects spent above goal
before initiating insulin therapy (or end of follow-up). Second,
we observed the level of A1C reached before insulin initiation
(or end of follow-up). Finally, we estimated overall glycemic
burden as defined by Brown and colleagues—the cumulative
amount by which A1C exceeded the 8% treatment goal. This
method sums the difference between measured or interpolated
Table 1. Subject Characteristics by Whether A1C Goal of 8% was Attained or Maintained
Characteristics Maintained 8% goal Attained, did not maintain 8% goal Never attained 8% goal
Number (%) of subjects 944. (24.3%) 2,241. (57.6%) . 706. (18.1%)
Age at SU/MET initiation* 61.9 (11.9) 59.2 (11.5) 53.8 (11.7)
Percent (%) female 51.1% 49.0% 47.2%
Diabetes duration (years) 4.2 (3.2) 4.3 (3.1) 4.0 (2.8)
Body mass index at SU/MET initiation 34.2 (7.6) 34.2 (7.3) 34.9 (7.5)
Weight change (pounds) at end offollow-up* −12.2 (19.1) −9.9 (18.5) −6.9 (16.4)
Presence of cardiovascular disease* 30.1% 28.1% 14.9%
Presence of congestive heart failure* 15.4% 13.8% 7.7%
Presence of micro/macroalbuminuria* 37.6% 43.2% 47.9%
Mean dose of last SU dispense (Glyburide equivs)† 11.3 (7.8) 13.8 (7.5) 14.4 (7.3)
Distribution of last SU dose*
<5 mg/day 13.6% 5.9% 3.4%
5–9.9 mg/day 21.1% 12.4% 9.8%
10–14.9 mg/day 32.5% 33.3% 37.3%
15–19.9 mg/day 7.2% 9.8% 9.2%
≥20 mg/day 25.6% 38.6% 40.4%
Sulfonylurea possession ratio 0.79 (0.27) . 0.82 (0.24) 0.81 (0.26)
Mean dose of last metformin dispense (mg)† 1,675 (754) 1,913. (677) 1,865. (799) .
Distribution of last metformin dose*:
<1,000 mg/day 9.2% 4.6% 7.4%
1,000–1,499 mg/day 22.8% 13.5% 15.4%
1,500–1,999 mg/day 25.0% 19.6% 21.0%
2,000–2,499 mg/day 23.6% 33.3% 27.9%
≥2,500 mg/day 19.4% 29.1% 28.3%
Metformin possession ratio* 0.78 (0.26) 0.75 (0.26) 0.70 (0.30)
Added insulin* 18.1% 43.9% 67.6%
Numbers shown are means (standard deviations) or percentages
*Groups differ, P<.001
†Maintained 8% goal differs from other two groups, P<0.001
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burden is equivalent to 1 month of A1C at 9%, or 10 months of
A1C at 8.1%).
15 The result is expressed in “A1C months”.
We stratified patients into three groups: (1) those who
achieved and maintained A1C goal for the entire observation
period; (2) those who initially achieved but failed to maintain
goal; and (3) those who never attained goal. By definition,
subjects who attained and maintained A1C goal spent no time
above goal after attaining it, but could still accumulate
glycemic burden before the goal was attained. For those who
initially achieved but did not maintain goal, we calculated
months above goal from the first date the A1C was above goal
(after previously being below goal). Among subjects who never
attained the goal, months above goal equaled total observation
months. To control for differences between strata that might
affect the decision to initiate insulin, we constructed a Cox
regression model of time-to-insulin-addition, adjusting for age,
sex, diabetes duration, presence of cardiovascular disease,
congestive heart failure, micro- or macroalbuminuria, body
mass index, change in body weight, SU dose, metformin dose,
SU and metformin adherence, number of A1C tests, and level
of last A1C during observation. For subjects who either failed
to maintain goal or never attained goal, we estimated the time
to insulin addition with PROC LIFETEST, using a Kaplan–
Meier plot to display the proportion of patients that added
insulin over time.
Using electronic medication dispensing records, we ascer-
tained the dose of each SU and metformin prescription.
Glyburide was the SU dispensed 98% of the time. When an
SU other than glyburide was used, we converted the daily dose
of the prescribed SU to “glyburide equivalents” based on
maximum doses of each agent.
16 We estimated adherence to
each of the medications using the medicine possession ratio,
calculated as the total days supply of dispensed medications
divided by the number of days of observation.
17 Age and sex
were extracted from membership records. We calculated body
mass index from weight and height measurements taken
before SU/MET initiation and calculated weight change based
on the last weight measured during observation. From the
electronic medical records, we identified presence of cardio-
vascular disease or congestive heart failure using the following
ICD-9-CM codes: myocardial infarction, 410.xx; stroke, 430.
xx–432.xx, 434.xx–436.xx, 437.1; other atherosclerotic cardio-
vascular disease, 411.1, 411.8, 413.xx, 414.0, 414.8, 414.9,
429.2; congestive heart failure, 428.xx. From laboratory data,
we identified subjects with microalbuminuria (albumin excre-
tion rate between 30 and 300 mg/day) or macroalbuminuria
(albumin excretion rate > 300 mg/day or serum creatinine
> 1.5 mg/dL or 24-hour urine protein > 165 mg/day).
All analyses were conducted using SAS statistical software
version 8.2 (SAS Institute, Cary, NC). The study was reviewed
and approved by the Institutional Review Board of Kaiser
Permanente’s Center for Health Research.
RESULTS
Subjects were followed for a mean of 54.6±28.6 months.
Nearly one-fifth (18.1%) of subjects failed to attain the A1C goal
of 8%, while just 24.3% reached and maintained that goal
(Table 1). Patients who never attained A1C < 8% were signifi-
cantly younger (53.8±11.7 years) than those who maintained
A1C < 8% (61.9±11.9 years, P<.001) and those who attained
but failed to maintain the 8% goal (59.2±11.5 years, P<.001).
All groups, on average, lost weight. However, patients who
maintained goal lost 12.2±19.1 lbs, those who did not maintain
goal lost 9.9±18.5 lbs, and those who never attained goal lost
6.9±16.4 pounds (P<.001 all comparisons). Last observed
doses of both metformin and SU were significantly lower among
those who maintained goal than among those who never
attained or failed to maintain goal. Adherence to SU as
Table 2. Mean (Standard Deviation) A1C, Months Above and
Below 8% Goal, and Glycemic Burden, by Whether Goal was
Attained and Maintained
Parameters Maintained
8% goal
Attained, did
not maintain
8% goal
Never
attained 8%
goal
Mean HbA1c Levels
Before SU/MET* 8.8% (1.6%) 9.1% (1.4%) 10.3% (1.7%)
First HbA1c After
SU/MET*
7.8% (1.4%) 8.1% (1.3%) 9.9% (1.4%)
Best HbA1c during
SU/MET*
6.3% (0.7%) 6.7% (0.7%) 9.2% (1.2%)
Mean HbA1c during
SU/MET*
7.2% (0.8%) 8.1% (0.8%) 10.0% (1.3%)
Last HbA1c of
follow-up*
6.8% (0.7%) 8.4% (1.6%) 10.3% (1.6%)
Mean number of
HbA1c tests
per year
2.1 (0.9) 2.3 (1.0) 2.0 (1.3)
Mean months
Until goal was
attained
10.3 (14.2) 9.2 (11.6) –
Below goal once it
was attained*
44.6 (29.8) 17.1 (15.3) –
Above goal after (if)
attaining it
– 35.8 (25.5) –
Total Follow-up* 54.9 (28.8) 62.1 (26.3) 30.1 (20.8)
Mean Glycemic
Burden*†
11.1 (28.8) 31.8 (40.1) 63.9 (65.6)
*Groups differ, P<.001
†One unit of burden equals 1 month of HbA1c at 9%, or 10 months at 8.1%
Table 3. Predictors of Insulin Addition from Multivariate Cox
Proportional Hazards Regression Model
Parameters Hazard ratio
(95% CI)
P value
Maintained HbA1c < 8% (referent) 1.00 –
Attained, did not maintain 8% 1.15 (0.96–1.01) 0.131
Never attained 8% 4.60 (3.65–5.79) <0.0001
Age (per 5 years) 0.99 (0.96–1.01) 0.308
Female sex 1.13 (1.02–1.26) 0.023
Duration of diabetes 0.97 (0.96–0.99) 0.005
Cardiovascular disease 0.95 (0.83–1.08) 0.415
Congestive heart failure 0.88 (0.74–1.04) 0.119
Micro-/macroalbuminuria 1.02 (0.92–1.14) 0.663
Baseline body mass index 1.02 (1.01–1.03) 0.0001
Weight change during follow-up
(per 5 lbs)
1.08 (1.06–1.09) <0.0001
Daily dose of sulphonylurea
(per 5 mg of Glyburide)
1.06 (1.03–1.10) 0.001
Daily dose of metformin (per 500 mg) 0.93 (0.89–0.98) 0.002
Mean HbA1c tests per year of follow-up 1.75 (1.68–1.83) <0.0001
Last HbA1c of follow-up 1.27 (1.23–1.31) <0.0001
Sulfonylurea possession ratio 1.95 (1.50–2.55) <0.0001
Metformin possession ratio 1.86 (1.47–2.34) <0.0001
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across the three groups. However, metformin adherence (pos-
sessionratio)wasbestamongthosewhomaintainedgoal(0.78±
0.26),loweramongthosewhoattainedbutdidnotmaintaingoal
(0.75±0.26), and worst among those who never attained goal
(0.70±0.30, P<.001 all comparisons).
Subjects who attained A1C goal had similar mean A1C
values before and immediately after initiating SU/MET, re-
gardless of whether they maintained the goal (Table 2). Those
who maintained the goal had a mean A1C of 8.8±1.6% before
and 7.8±1.4% after SU/MET; the corresponding means were
9.1±1.4% and 8.1±1.3% among those who failed to maintain
the goal A1C. Those who never attained 8% had mean A1C
levels of 10.3±1.7% before and 9.9±1.4% after initiating SU/
MET (P<.001, compared to both groups). Subjects who
maintained an A1C < 8% took longer to attain the goal than
those who failed to maintain it (10.3±14.2 vs 9.2±
11.6 months, P<.022), but maintainers continued below 8%
for over twice as long (44.6±29.8 vs 17.1±15.3 months, P<.001).
Inallgroups, patientsaveragedatleast 2A1Cmeasurementsper
year. Because patients who never attained goal were more likely
to add insulin, they had the shortest total follow-up time, but
incurred over twice the glycemic burden (63.9±65.6 A1C
months) comparedtopatientswho attained but did not maintain
the goal (31.8±40.1 A1C months, P<.001).
Patients who never attained the goal were over four times
more likely to add insulin than those who maintained goal
(Table 3; HR 4.60, 95% CI 3.65−5.79, P<.0001). However, after
accounting for other factors, subjects who attained but did not
maintain A1C < 8% were not significantly more likely to initiate
insulin than those who maintained the goal. Higher doses of
SU but lower doses of metformin were predictive of insulin
addition, as was better adherence to each drug. Higher body
mass index at SU/MET initiation and greater weight gain (or
less loss) predicted insulin use. Women were 13% more likely
to initiate insulin (1.13, 1.02–1.26, P=.023). Age and comor-
bidities were not significant factors.
Figure 1 displays Kaplan–Meier estimates of time to insulin
addition for those who attained but failed to maintain 8%
(calculated from the point at which goal was no longer
maintained) and for those who never attained 8%. By
24 months, about 50% of subjects who never attained goal
had added insulin. In contrast, it took about 60 months for
50% of those who attained but did not maintain goal to add
insulin (log-rank test, P<.0001).
DISCUSSION
In this retrospective longitudinal cohort study, we found that
over 80% of the 3,891 type 2 diabetes patients newly initiating
SU/MET achieved the A1C goal of 8%. However, most patients
who succeeded in reaching that goal were unable to maintain
it. Despite A1C levels in excess of the then-recommended level
for therapeutic action and well in excess of the currently
recommended level of 7%,
18 patients continued SU/MET
therapy alone for an average of nearly 3 years. We calculated
months above target from the test date of the first elevated
A1C, likely resulting in an underestimate of the actual time
above goal. Because of this long delay, patients sustained
Figure 1. Kaplan–Meier analysis of time to insulin addition.
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A1C levels of 9%. Moreover, 18% of patients never attained the
8% goal with SU/MET, yet continued that therapy for an
average of 30 months while reaching average A1C levels of
10%. These A1C levels 1–2% persistently above goal may result
in potentially avoidable diabetic complications. In the United
Kingdom Prospective Diabetes Study (UKPDS), for example,
each 1% reduction in mean A1C was associated with a 21%
reduction in any diabetes-related end point.
19
Although previous studies in this and other study settings
have demonstrated that clinical inertia is common in the
treatment of hyperglycemia,
6,10–12,15 to our knowledge, the
current study is the first to quantify clinical inertia over several
years. Our study focused on SU/MET patients whose next
therapeutic step (according to KPNW internal guidelines) was
insulin, a population in which clinical inertia may be particu-
larly problematic. Previous studies have described the concept
of “psychological insulin resistance,” in which patients and
providers are reluctant to initiate subcutaneous insulin ther-
apy.
20–24 Our results suggest that such reluctance may lead to
long periods of elevated glycemic levels that put patients at
increased risk for diabetes complications. We could not
ascertain the reasons for delaying insulin initiation in our
data. Although there are legitimate clinical reasons for not
initiating insulin, such as advanced age or heart failure, these
variables did not predict insulin initiation in our multivariate
model. Concern about weight gain might also deter insulin
use, but in our model, higher baseline BMI and greater weight
gain predicted insulin initiation, confirming the value of weight
loss in reducing hyperglycemia. Thus, it appears that unmea-
sured variables such as psychological insulin resistance likely
contribute to the delay of therapy intensification.
Reluctance to initiate insulin would not be the only
explanation for why patients continue SU/MET alone despite
inadequate glycemic control. For example, we found that less
than half of patients were receiving maximum doses of either
SU or metformin during their SU/MET, suggesting that dose
adjustments within their current therapy could improve
glycemic control. Mean doses of SU and metformin, however,
were higher in subjects who either failed to maintain or who
never attained goal than among those who attained and
maintained goal. After multivariate adjustment, higher doses
of metformin did slow progression to insulin, but higher doses
of SU predicted insulin initiation. The therapeutic benefit of
increasing doses beyond those we report could not be deter-
mined from these data.
The lower doses in those who achieved and maintained an
A1C < 8% may reflect the greater difficulty patients have
achieving the goal as their A1C levels become higher. As our
data show, patients who never attained goal had substantially
higher A1C levels before initiating SU/MET compared to those
who attained goal. These results are consistent with recent
reports of secondary failure of SU and metformin monotherapy
conducted in the same setting.
25,26 Those studies also demon-
strated that the duration of an individual agents’ success was
inversely related to the A1C reduction achieved in the first year
of use. We observed a similar pattern in the current study—
subjects who attained the A1C goal reduced their A1C by about
one percentage point at the first measurement after SU/MET
initiation, while those who failed to reach goal had mean A1C
levels still near 10%. Adherence to metformin might explain
some of the difference in success, as it was significantly greater
among those who maintained goal compared to those who
never attained 8%. However, after controlling for other factors,
better adherence to both SU and metformin predicted insulin
initiation. This finding may reflect a greater willingness among
adherent patients to start insulin therapy, or a greater sense
that these patients had maximized the benefit of SU/MET. In
any case, SU/MET is not a long-term therapy solution for most
patients, regardless of dose or adherence. Given that three-
fourths of our study subjects never attained or failed to
maintain A1C goal, our results suggest that patients will most
benefit from the new guidelines that lowered A1C goal with
more aggressive intensification of glycemic control regimens,
perhaps by initiating insulin sooner.
Another therapeutic option when SU/MET fails is the
addition of other oral agents, such as thiazolidinediones. The
ADA/EASD consensus statement offers this option when A1C is
close to goal,
9 but these drugs are not widely used in our study
setting. We chose to exclude the 414 potential subjects who
initiated a third oral agent from our study because they or their
clinicians did not follow the predominant practice pattern in our
setting, and therefore, did not represent most SU/MET patients.
Our results are not likely specific to the study setting.
Previous research has shown that members of the study HMO
receive more guideline-adherent care and achieve lower-than-
average risk factors levels, with mean A1C levels of 7.5%.
6,27,28
Our subjects were not a neglected subset of the HMO—they
averaged over two A1C measurements per year and nearly 10
measurements during the study period. In addition, our study
likely understates the glycemic burden accumulated during
SU/MET because we could not follow patients beyond the end
of observation. Thus, the months over A1C goal that we
observed is the lower limit incurred preceding therapeutic
action. Our findings are especially relevant now that the recent
ADA/EASD consensus statement recommends insulin as the
third line agent when A1C is greater than 7% with SU/MET.
9
Furthermore, a recent observational study conducted in New
England concluded that use of multiple oral antidiabetic
agents may serve as a marker for uncontrolled diabetes.
29
Considering that the Diabetes Attitudes, Wishes, and Needs
(DAWN) study recently demonstrated that resistance to
injected insulin therapy is an international phenomenon,
14
patients worldwide may be experiencing glycemic burden
levels at least similar to and probably greater than those we
report. However, it is important to note that we did not follow
patients beyond insulin initiation. Therefore, we do not know
the extent to which our study subjects achieved glycemic
control once therapy was intensified. We may also have under-
estimated the proportion of patients who initiated insulin
because it could have been obtained from non-plan sources.
To maximize potential follow-up time, we limited the period in
which patients could initiate SU/MET to 1996–2000. Under the
HMO treatment algorithm then in place, most of our study
subjects were receiving SU monotherapy before adding metfor-
min. The current HMO treatment algorithm now recommends
metformin as the first-line agent, followed by addition of SU.
Our results may not apply to the new therapeutic pathway.
Because we had relatively few subjects who added SU to
metformin monotherapy, and even fewer who simultaneously
initiated SU and metformin, we could not test whether different
therapeutic pathways to SU/MET produced different levels of
glycemic burden. However, a recent study showed that glycemic
deterioration resumed in about 6 months after SU was added to
457 Nichols et al.: Delay of Insulin Addition to Oral Combination Therapy JGIMmetformin; the authors concluded that their results were
consistent with UKPDS findings of early addition of metformin
to SU monotherapy.
4,7 Thus, it is unlikely that different path-
ways would generate different levels of glycemic burden.
Because diabetes is a progressive disease, many patients
will eventually require insulin supplementation to achieve
glycemic control targets.
1 Patients in this setting treated with
oral combination therapy are often not treated with maximal
doses and appear to delay insulin initiation for prolonged
periods, thereby, incurring substantial, and perhaps, prevent-
able glycemic burden. These findings warrant additional
studies examining the benefits of rapid titration to maximum
doses and earlier initiation of insulin therapy. In addition,
further research is needed to understand the clinician, patient,
and system barriers to therapy intensification.
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